Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]

M. Fassnacht; G. Assie; E. Baudin; G. Eisenhofer; C. de la Fouchardiere; H. R. Haak; R. de Krijger; F. Porpiglia; M. Terzolo; A. Berruti

doi:10.1016/j.annonc.2022.12.006

Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]

M. Fassnacht
, G. Assie
, E. Baudin
, G. Eisenhofer
, C. de la Fouchardiere
, H. R. Haak
, R. de Krijger
, F. Porpiglia
, M. Terzolo
, A. Berruti
,

Department of Pathology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

Abstract

The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	631
Number of pages	1
Journal	Annals of Oncology
Volume	34
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.12.006
Publication status	Published - Jul 2023

Access to Document

10.1016/j.annonc.2022.12.006

1-s2.0-S0923753422047755-mainFinal published version, 149 KBLicence: Taverne

Fingerprint

Dive into the research topics of 'Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]'. Together they form a unique fingerprint.

Cite this

Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., Fouchardiere, C. D. L., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., Berruti, A. (2023). Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]. Annals of Oncology, 34(7), 631. https://doi.org/10.1016/j.annonc.2022.12.006

@article{ae33dc305c3347b792e5d4f87f8821f7,

title = "Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up{"}: [Annals of Oncology volume 31 (2020) 1476-1490]",

abstract = "The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.",

author = "M. Fassnacht and G. Assie and E. Baudin and G. Eisenhofer and Fouchardiere, \{C. de la\} and Haak, \{H. R.\} and \{de Krijger\}, R. and F. Porpiglia and M. Terzolo and A. Berruti",

note = "Publisher Copyright: {\textcopyright} 2022 European Society for Medical Oncology",

year = "2023",

month = jul,

doi = "10.1016/j.annonc.2022.12.006",

language = "English",

volume = "34",

pages = "631",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "7",

}

Fassnacht, M, Assie, G, Baudin, E, Eisenhofer, G, Fouchardiere, CDL, Haak, HR, de Krijger, R, Porpiglia, F, Terzolo, M, Berruti, A 2023, 'Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]', Annals of Oncology, vol. 34, no. 7, pp. 631. https://doi.org/10.1016/j.annonc.2022.12.006

Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]. / Fassnacht, M.; Assie, G.; Baudin, E. et al.
In: Annals of Oncology, Vol. 34, No. 7, 07.2023, p. 631.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas

T2 - ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]

AU - Fassnacht, M.

AU - Assie, G.

AU - Baudin, E.

AU - Eisenhofer, G.

AU - Fouchardiere, C. de la

AU - Haak, H. R.

AU - de Krijger, R.

AU - Porpiglia, F.

AU - Terzolo, M.

AU - Berruti, A.

PY - 2023/7

Y1 - 2023/7

N2 - The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85144797760

U2 - 10.1016/j.annonc.2022.12.006

DO - 10.1016/j.annonc.2022.12.006

M3 - Comment/Letter to the editor

C2 - 36564283

AN - SCOPUS:85144797760

SN - 0923-7534

VL - 34

SP - 631

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]

Abstract

Access to Document

Other files and links

Fingerprint

Cite this